International
The Morning Science

What science found today

‹
 

Policy

FDA Adds Optic Neuropathy Warning to GLP-1 RA Drug Labels

Science-Based Medicine · By David Weinberg ·

FDA Adds Optic Neuropathy Warning to GLP-1 RA Drug Labels

The Brief

  • The FDA has added an optic neuropathy warning to the labels of GLP-1 receptor agonist (GLP-1 RA) drugs.
  • Science-Based Medicine says a causal relationship between GLP-1 RAs and "eye stroke" remains tenuous.
  • The same source describes the FDA's decision as reasonable.

Why it matters

The label change reflects a regulatory decision made despite a causal link that is still described as tenuous, so readers should weigh the warning against the limited evidence behind it.

Who’s affected

  • patients taking GLP-1 receptor agonist drugs
  • clinicians prescribing GLP-1 receptor agonist drugs

A causal relationship between GLP-1 RAs and "eye stroke" remains tenuous, but the FDA’s decision seems reasonable The post FDA Adds Optic Neuropathy Warning to GLP-1 RA Drug Labels first appeared on Science-Based Medicine .

How do you feel about this?

0 Comments

    FDA Adds Optic Neuropathy Warning to GLP-1 RA Drug Labels – The Morning Science